KEGG   DRUG: EculizumabHelp
Entry
D03940                      Drug                                   

Name
Eculizumab (USAN/INN);
Eculizumab (genetical recombination) (JAN);
Soliris (TN)
Product
Remark
Therapeutic category: 6399
ATC code: L04AA25
Product: D03940<JP/US>
Efficacy
Immunosuppressant, Anti-complement C5 antibody
  Disease
Paroxysmal nocturnal hemoglobinuria [DS:H01053]
Atypical hemolytic uremic syndrome [DS:H01434]
Comment
Monoclonal antibody
Target
C5 [HSA:727] [KO:K03994]
  Pathway
hsa04610  Complement and coagulation cascades
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA25 Eculizumab
      D03940  Eculizumab (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D03940  Eculizumab (USAN/INN); Eculizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Organismal systems
   Complement and coagulation
    C5
     D03940  Eculizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D03940
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03940
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D03940
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D03940
BRITE hierarchy
Other DBs
CAS: 219685-50-4
PubChem: 47205928
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system